What if the very speed that delivered lifesaving vaccines also cemented a single-technology playbook that looks nimble in peacetime but brittle under pressure when the next pathogen demands different strengths and a steadier supply chain than speed alone can provide? The COVID-19 race crowned mRNA
Rising failure rates for single-mechanism therapies in heterogeneous solid tumors have pushed oncology beyond single-target tinkering and into platform-centric thinking that prizes modularity, combinability, and consistent manufacturability across programs. In this shift, antibody-drug conjugates
The drumbeat behind next-generation biologics has been unmistakable, yet the loudest voices in today’s pipelines keep returning to a sobering reality: delivery is not polish at the finish line, it is the race itself, where fragile molecules, strict dosing windows, and hard-to-reach tissues force
Chronic HIV infection, even under suppressive antiretroviral therapy, can trap the immune system in a state of simmering alarm that never fully resolves and quietly erodes the fitness of the very T cells needed for durable control of the virus. That conundrum has intensified attention on the small
In an era where supply chain resilience and access to life-saving therapies dominate healthcare discussions, AstraZeneca's announcement of a $2 billion investment in Maryland facilities has captured significant attention, raising critical questions about domestic production. This ambitious
The pharmaceutical landscape is on the brink of a seismic shift with the introduction of the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program, a bold initiative designed to cut the review timeline for drug and biological product applications from the standard 10-12 months down to
